Sanwa Kagaku Kenkyusho
Nagoya, Japan· Est.
Japanese pharmaceutical company developing novel treatments for metabolic and orphan diseases, with a lead candidate for acromegaly.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese pharmaceutical company developing novel treatments for metabolic and orphan diseases, with a lead candidate for acromegaly.
MetabolicRare DiseasesEndocrine
Technology Platform
Small molecule drug development with focus on metabolic and orphan diseases, utilizing open innovation and strategic alliances for R&D.
Opportunities
Growth through orphan drug development with favorable regulatory pathways in Japan and globally, plus expansion through strategic partnerships for co-development and market access initiatives.
Risk Factors
Clinical trial risks for lead candidate paltusotine, dependency on niche markets with limited patient populations, and competitive pressure from larger pharmaceutical companies in metabolic disorders.
Competitive Landscape
Competes with larger endocrine-focused pharmaceutical companies like Novartis, Pfizer, and Ipsen in acromegaly, but differentiates through specialized focus on Japanese market and orphan disease expertise.